BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer.

Trial Profile

BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Ridaforolimus (Primary) ; Cetuximab
  • Indications Colon cancer; Head and neck cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Feb 2013 Planned end date changed from 1 Dec 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 22 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 May 2012 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top